WARFARIN POTASSIUM

First approved in 1954

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H15O4.K
Molecular Weight	346.4183
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[K+].CC(=O)CC(C1=CC=CC=C1)C2=C([O-])C3=C(OC2=O)C=CC=C3

InChI

InChIKey=WSHYKIAQCMIPTB-UHFFFAOYSA-M

InChI=1S/C19H16O4.K/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22;/h2-10,15,21H,11H2,1H3;/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	K
Molecular Weight	39.0983
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C19H15O4
Molecular Weight	307.32
Charge	-1
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf | https://www.drugbank.ca/drugs/DB00682 | https://www.ncbi.nlm.nih.gov/pubmed/23618698

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Warfarin is marketed under the brand name Coumadin among others. Coumadin (crystalline warfarin sodium) is an anticoagulant which acts by inhibiting vitamin K-dependent coagulation factors. Chemically, it is 3-(α-acetonylbenzyl)-4-hydroxycoumarin and is a racemic mixture of the R- and S-enantiomers. Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. It is also indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient’s VKORC1 genotype. Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vitamin k epoxide reductase complex subunit 1 isoform 1 22 Target ID: CHEMBL1930 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6712738 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/23618698	Inhibitor 8504		24.7 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Venous thrombosis 9 Sources: https://www.drugs.com/dosage/warfarin.html	Primary	Approved 8583	COUMADIN Approved Use Warfarin sodium tablets are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Warfarin sodium tablets are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin sodium tablets are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Launch Date 1954
Myocardial infarction 125 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf https://www.drugs.com/pro/warfarin.html	Preventing	Approved 8583	COUMADIN Approved Use Warfarin sodium tablets are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Warfarin sodium tablets are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin sodium tablets are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Launch Date 1954
Thromboembolic complications associated with atrial fibrillation 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf	Preventing	Approved 8583	COUMADIN Approved Use Warfarin sodium tablets are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Warfarin sodium tablets are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin sodium tablets are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Launch Date 1954

C_max

Value	Dose	Co-administered	Analyte	Population
2186 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19552747	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		WARFARIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
52278 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19552747	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		WARFARIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
7 day DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf	single, oral		WARFARIN plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
32.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19552747	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		WARFARIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf	single, oral		WARFARIN plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
125 mg single, oral Overdose Dose: 125 mg Route: oral Route: single Dose: 125 mg Sources: https://pubmed.ncbi.nlm.nih.gov/14639058	unhealthy, 43 Health Status: unhealthy Age Group: 43 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/14639058	Disc. AE: Vomiting, Loss of consciousness... AEs leading to discontinuation/dose reduction: Vomiting Loss of consciousness Sources: https://pubmed.ncbi.nlm.nih.gov/14639058
150 mg single, oral Overdose Dose: 150 mg Route: oral Route: single Dose: 150 mg Sources: https://pubmed.ncbi.nlm.nih.gov/14639058	unhealthy, 44 Health Status: unhealthy Age Group: 44 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/14639058	Disc. AE: Drowsiness... AEs leading to discontinuation/dose reduction: Drowsiness Sources: https://pubmed.ncbi.nlm.nih.gov/14639058
540 mg single, oral Overdose Dose: 540 mg Route: oral Route: single Dose: 540 mg Sources: https://pubmed.ncbi.nlm.nih.gov/24674108	healthy, 59 Health Status: healthy Age Group: 59 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/24674108	Sources: https://pubmed.ncbi.nlm.nih.gov/24674108
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26658807	unhealthy, 64 Health Status: unhealthy Age Group: 64 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/26658807	Disc. AE: Hemoptysis, Hematuria... AEs leading to discontinuation/dose reduction: Hemoptysis Hematuria Dyspnea Cough Sources: https://pubmed.ncbi.nlm.nih.gov/26658807
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf	Disc. AE: Bleeding... AEs leading to discontinuation/dose reduction: Bleeding (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf

AEs

AE	Significance	Dose	Population
Loss of consciousness	Disc. AE	125 mg single, oral Overdose Dose: 125 mg Route: oral Route: single Dose: 125 mg Sources: https://pubmed.ncbi.nlm.nih.gov/14639058	unhealthy, 43 Health Status: unhealthy Age Group: 43 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/14639058
Vomiting	Disc. AE	125 mg single, oral Overdose Dose: 125 mg Route: oral Route: single Dose: 125 mg Sources: https://pubmed.ncbi.nlm.nih.gov/14639058	unhealthy, 43 Health Status: unhealthy Age Group: 43 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/14639058
Drowsiness	Disc. AE	150 mg single, oral Overdose Dose: 150 mg Route: oral Route: single Dose: 150 mg Sources: https://pubmed.ncbi.nlm.nih.gov/14639058	unhealthy, 44 Health Status: unhealthy Age Group: 44 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/14639058
Cough	Disc. AE	5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26658807	unhealthy, 64 Health Status: unhealthy Age Group: 64 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/26658807
Dyspnea	Disc. AE	5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26658807	unhealthy, 64 Health Status: unhealthy Age Group: 64 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/26658807
Hematuria	Disc. AE	5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26658807	unhealthy, 64 Health Status: unhealthy Age Group: 64 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/26658807
Hemoptysis	Disc. AE	5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26658807	unhealthy, 64 Health Status: unhealthy Age Group: 64 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/26658807
Bleeding	grade 5 Disc. AE	10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	substrate 1193 inhibitor 2438

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2C19 1119 CYP2C8 810 CYP2C18 149 CYP1A2 1197

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2C9 2497	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406237/	yes [Ki 8 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2C18 149	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf#page=14 Page: 14.0	yes
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf#page=14 Page: 14.0	yes
CYP2C8 810	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf#page=14 Page: 14.0	yes
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf#page=14 Page: 14.0	yes	likely (co-administration study) Comment: Inhibitors of CYP2C9, 1A2, and/or 3A4 have the potential to increase the effect (increase INR) of warfarin by increasing the exposure of warfarin; Inducers of CYP2C9, 1A2, and/or 3A4 have the potential to decrease the effect (decrease INR) of warfarin by decreasing the exposure of warfarin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf#page=14 Page: 14.0
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf#page=14 Page: 14.0	yes	likely (co-administration study) Comment: Inhibitors of CYP2C9, 1A2, and/or 3A4 have the potential to increase the effect (increase INR) of warfarin by increasing the exposure of warfarin; Inducers of CYP2C9, 1A2, and/or 3A4 have the potential to decrease the effect (decrease INR) of warfarin by decreasing the exposure of warfarin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf#page=14 Page: 14.0
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf#page=14 Page: 14.0	yes	yes (pharmacogenomic study) Comment: If the patient’s CYP2C9 and/or VKORC1 genotype are known, consider these ranges in choosing the initial dose. Patients with CYP2C9 1/3, 2/2, 2/3, and 3/3 may require more prolonged time (>2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen than patients without these CYP variants; Inhibitors of CYP2C9, 1A2, and/or 3A4 have the potential to increase the effect (increase INR) of warfarin by increasing the exposure of warfarin; Inducers of CYP2C9, 1A2, and/or 3A4 have the potential to decrease the effect (decrease INR) of warfarin by decreasing the exposure of warfarin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf#page=14 Page: 14.0

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY560195	https://www.001chemical.com/chem/5543-57-7
001 Chemical	DY560196	https://www.001chemical.com/chem/5543-58-8
3B Scientific (Wuhan) Corp	3B3-029941	http://www.3bsc.com/index/pro_info.php?id=51198
AA Blocks	AA003248	https://www.aablocks.com/goods/Goods/detail?id=AA003248
abcr GmbH	AB463721	http://www.abcr.de/shop/en/AB463721
AbMole Bioscience	M6059	http://www.abmole.com/products/warfarin.html
Acadechem	ACDS-030017	http://www.acadechemical.com/product/104716
Achemtek	0104-006074	http://www.achemtek.com/81-81-2
Acros Organics	AC454680100	https://www.fishersci.com/shop/products/4-hydroxy-3-3-oxo-1-phenylbutyl-coumarin-97-acros-organics/AC454680100
AHH Chemical co.,ltd	MT-60432	http://www.ahhchemical.com/product/MT-60432.html
AK Scientific, Inc. (AKSCI)	N022	http://www.aksci.com/item_detail.php?cat=N022
Alfa Chemistry	AP5543588	https://reagents.alfa-chemistry.com/product/r-warfarin-cas-5543-58-8-13054.html
Alsachim	1632	http://www.alsachim.com/product-C2641-glo.bal-view.html
Ambinter	Amb19134261	http://www.ambinter.com/reference/19134261
Ambinter	Amb1967203	http://www.ambinter.com/reference/1967203
Ambinter	Amb22269258	http://www.ambinter.com/reference/22269258
Aurora Fine Chemicals LLC	K00.332.840	http://online.aurorafinechemicals.com/info?ID=K00.332.840
Avantor Inc	101096-426	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101096-426
Avantor Inc	101096-428	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101096-428
BLD Pharm	BD634785	http://www.bldpharm.com/products/951658-59-6.html
BOC Sciences	75472-93-4	https://www.bocsci.com/warfarin-d5-cas-75472-93-4-item-418144.html
BOC Sciences	773005-79-1	https://www.bocsci.com/r-warfarin-d5-cas-773005-79-1-item-485323.html
BOC Sciences	791013-22-4	https://www.bocsci.com/s-warfarin-d5-cas-791013-22-4-item-485322.html
Boerchem	BC209814	http://www.boerchem.com/?product_35612.html
Chem Scene	CS-2926	http://www.chemscene.com/81-81-2.html
ChemBridge	5103031	http://www.hit2lead.com/comp.asp?db=SC&id=5103031
Chemchart	cc-warfarin	http://chemchart.com/warfarin-detail.html
Chemenu	CM110351	http://www.chemenu.com/products/CM110351
ChemMol	30105039	http://www.chemmol.com/chemmol/30105039.html
ChemMol	44026663	http://www.chemmol.com/chemmol/44026663.html
ChemMol	49416852	http://www.chemmol.com/chemmol/49416852.html
ChemMol	96700285	http://www.chemmol.com/chemmol/96700285.html
ChemMol	96701916	http://www.chemmol.com/chemmol/96701916.html
Chemspace	CSSB00000064351	https://chem-space.com/CSSB00000064351
Clearsynth	CS-O-10379	https://www.clearsynth.com/en/CSO10379.html
DC Chemicals	DC9053	http://www.dcchemicals.com/product_show-Warfarin.html
Debye Scientific	DB-052729	http://www.debyesci.com/cas_5543-57-7.html
Debye Scientific	DB-052730	http://www.debyesci.com/cas_5543-58-8.html
Enamine	Z1692482575	https://www.enaminestore.com/catalog/Z1692482575
Finetech	FT-0635767	http://www.finetechnology-ind.com/prod/detail/pub/5543-57-7.html
Finetech	FT-0635768	http://www.finetechnology-ind.com/prod/detail/pub/5543-58-8.html
Glentham Life Sciences	GL2208	http://www.glentham.com/products/product/GL2208/
Glentham Life Sciences	GP7659	http://www.glentham.com/products/product/GP7659/
Huateng Pharma	F80010283	http://en.huatengsci.com/product/Warfarin.html
LGC Standards	DRE-C17940000	https://www.lgcstandards.com/US/en/p/DRE-C17940000
LGC Standards	DRE-XA17940000AL	https://www.lgcstandards.com/US/en/p/DRE-XA17940000AL
LGC Standards	LGCAMP0638.00-11	https://www.lgcstandards.com/US/en/p/LGCAMP0638.00-11
LGC Standards	LGCFOR0638.00	https://www.lgcstandards.com/US/en/p/LGCFOR0638.00
LGC Standards	MM0638.00	https://www.lgcstandards.com/US/en/p/MM0638.00
mcule	MCULE-1618253893	https://mcule.com/MCULE-1618253893/
MedChem Express	HY-B0687	https://www.medchemexpress.com/Warfarin.html
Molcore	MC560195	https://www.molcore.com/product/5543-57-7
Molcore	MC560196	https://www.molcore.com/product/5543-58-8
MuseChem	A000086	https://www.musechem.com/product/A000086.html
Oakwood	245858	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=167707&ExtHyperLink=1
OChem	4139	http://www.ocheminc.com/index.php?act=psearch&pid=006W854
Parchem	30305	http://www.parchem.com/chemical-supplier-distributor/Warfarin-020305.aspx
Selleck Chemicals	S4545	http://www.selleckchem.com/products/warfarin.html
Sigma-Aldrich	1719000_USP	https://www.sigmaaldrich.com/catalog/product/usp/1719000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	45706_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/45706?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A2250_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/a2250?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	BP672_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/bp672?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	N13750_SUPELCO	https://www.sigmaaldrich.com/catalog/product/supelco/n13750?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S014360	http://www.sinfoobiotech.com/product/1017758
Smolecule	S547079	http://www.smolecule.com/products/s547079
Smolecule	S919271	https://www.smolecule.com/products/s919271
THE BioTek	bt-285232	https://www.thebiotek.com/product/inhibitors/bt-285232
Vesino Industrial Co Ltd	VC30411	http://www.vsnchem.com/goto/product/22479/
Yuhao Chemical	RT6489	http://www.chemyuhao.com/81-81-2.html

PubMed

Title	Date	PubMed
Abdominal wall hematoma as a complication of warfarinization.	2001-04	11267821
Spontaneous subcapsular renal hematoma secondary to anticoagulant therapy.	2001-04	11257671
Behçet's disease with a large intracardiac thrombus: a case report.	2001-04	11250984
Warfarin therapy for an octogenarian who has atrial fibrillation.	2001-03-20	11255522
Subarachnoid haemorrhage.	2001-03-17	11265984
What is the optimal medical management of ischemic heart failure?	2001-03-17	11251129
Profile of moxifloxacin drug interactions.	2001-03-15	11249829
Dalteparin vs warfarin in hip arthroplasty patients.	2001-03-12	11231726
Mild head injury, anticoagulants, and risk of intracranial injury.	2001-03-10	11253975
Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective.	2001-03-06	11242501
Vitamin K for warfarin-associated coagulopathy.	2001-03-03	11247582
Sneddon's syndrome: a case report.	2001-03	11270293
Perception of teratogenic risk of common medicines.	2001-03	11267734
Long-term results of venous revascularization for Paget-Schroetter syndrome in athletes.	2001-03	11265086
Prevention, diagnosis, and treatment of venous thromboembolic complications of gynecologic surgery.	2001-03	11262484
Increase in international normalized ratio associated with smoking cessation.	2001-03	11261541
The association of vitamin K status with warfarin sensitivity at the onset of treatment.	2001-03	11260056
A case report of warfarin resistance due to azathioprine and review of the literature.	2001-03	11253860
Evaluation of very low-dose subcutaneous vitamin K during postoperative warfarin therapy.	2001-03	11253854
Palliative care for the elderly.	2001-03	11252217
Treatment of the patient with deep vein thrombosis.	2001-03	11252215
Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction.	2001-03	11246058
Hemoptysis in patients with renal insufficiency : the role of flexible bronchoscopy.	2001-03	11243958
Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy.	2001-03	11243272
Improving medication safety across a multihospital system.	2001-03	11242719
Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation.	2001-03	11241016
Atrial fibrillation and stroke : concepts and controversies.	2001-03	11239205
Low-dose warfarin fails to prolong survival of dual lumen venous dialysis catheters.	2001-03	11239055
Mutations of the CYP2C9 gene and the response to warfarin.	2001-03	11231472
Antiphospholipid antibody syndrome and renal disease.	2001-03	11224691
When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment.	2001-03	11223323
Management of thrombosis in women with antiphospholipid syndrome.	2001-03	11219245
Acute spontaneous haematoma of the rectum.	2001-02-24	11219323
Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.	2001-02-15	11248285
Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2.	2001-02-15	11241250
What is the best emergency treatment for children who ingest warfarin rodenticide?	2001-02-05	11247620
Perioperative management and reversal of antithrombotic therapy.	2001-02	11270131
Thrombolysis and antithrombotic therapy for coronary artery disease.	2001-02	11270130
Antithrombotic therapy in valvular heart disease.	2001-02	11270129
Oral anticoagulants. Pharmacologic issues for use in the elderly.	2001-02	11270124
Anticoagulation and cataract surgery: a review of the current literature.	2001-02	11261903
[Incidence of tumors after treatment with oral anticoagulants].	2001-02	11233836
Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis.	2001-02	11216981
Need for increased dose of warfarin in HIV patients taking nevirapine.	2001-01-26	11216940
[Old adrenal hematoma: a case report].	2001-01	11235216
Regarding postoperative stroke after warfarin for cutaneous surgery.	2001-01	11231258
Catastrophic antiphospholipid antibody syndrome.	2001-01	11227622
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.	2001-01	11225565
Central retinal vein occlusion associated with primary pulmonary hypertension.	2001	11217943
Chondrodysplasia punctata and maternal warfarin use during pregnancy.	1975-03	1121966

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Prevention of Thromboembolism in Atrial Fibrillation Initial dose: 2 to 5 mg orally once a day Maintenance dose: 2 to 10 mg orally once a day Usual Adult Dose for Myocardial Infarction Initial dose: 2 to 5 mg orally once a day Maintenance dose: 2 to 10 mg orally once a day Usual Adult Dose for Deep Vein Thrombosis - Prophylaxis Initial dose: 2 to 5 mg orally once a day Maintenance dose: 2 to 10 mg orally once a day

Route of Administration: Oral

In Vitro Use Guide

Vitamin K-reductase activity was inhibited by approximately 13 and 8% respectively when microsomal preparations from TAS and HW animals were incubated with 50 uM vitamin K1 and 10 uM warfarin.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:31:06 GMT 2025` Edited by `admin` on `Mon Mar 31 18:31:06 GMT 2025`
Record UNII	I47IU4FOCO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

WARFARIN-POTASSIUM

Preferred Name

English

WARFARIN POTASSIUM

Common Name

English

WARFARIN POTASSIUM [ORANGE BOOK]

Common Name

English

POTASSIUM WARFARIN

Common Name

English

WARFARIN POTASSIUM [JAN]

Common Name

English

Warfarin potassium [WHO-DD]

Common Name

English

ATHROMBIN-K

Brand Name

English

WARFARIN-POTASSIUM [ISO]

Common Name

English

2H-1-BENZOPYRAN-2-ONE, 4-HYDROXY-3-(3-OXO-1-PHENYLBUTYL)-, POTASSIUM SALT

Common Name

English

3-(?-Acetonylbenzyl)-4-hydroxycoumarin potassium salt

Common Name

English

Classification Tree Code System Code

EPA PESTICIDE CODE

86005